Table 1.

Baseline and treatment characteristics stratified by achievement of benchmarked dosimetric criteria (mean lung dose ≤13.5 Gy and percent of lung volume receiving less than 5 Gy ≤55%)

Characteristic	Total	Yes	%	No	%	P-value
Sex
Female	108	78	54.2	30	65.2	.188
Male	82	66	45.8	16	34.8
Ethnicity
White	137	105	72.9	32	69.6	.958
African-American	14	10	6.9	4	8.7
Hispanic	26	19	13.2	7	15.2
Other	13	10	6.9	3	6.5
Tumor histology
Non-Hodgkin lymphoma	56	41	28.5	15	32.6	.592
Hodgkin lymphoma	134	103	71.5	31	67.4
Disease stage
I	19	17	11.8	2	4.4	.447
II	138	104	72.2	34	73.9
III	14	10	6.9	4	8.7
IV	19	13	9.0	6	13.0
Asthma/COPD
No	175	131	91.0	44	95.7	.306
Yes	15	13	9.0	2	4.4
ABVD
No	68	49	34.0	19	41.3	.370
Yes	122	95	66.0	27	58.7
Smoking history
No	151	114	79.2	37	80.4	.853
Yes	39	30	20.8	9	19.6
Bulky disease (>10 cm)
No	75	63	43.8	12	26.1	.033
Yes	115	81	56.3	34	73.9
Required salvage chemotherapy
No	146	119	82.6	27	58.7	.001
Yes	44	25	17.4	19	41.3
Bleomycin toxicity
No	156	118	81.9	38	82.6	.919
Yes	34	26	18.1	8	17.4
Deep-inspiration breath-hold
No	80	50	34.7	30	65.2	< .001
Yes	110	94	65.3	16	34.8
History of stem cell transplant
Yes	43	24	16.7	19	41.3	.001
No	147	120	83.3	27	58.7
Brentuximab
No	170	133	92.4	37	80.4	.022
Yes	20	11	7.6	9	19.6

ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; COPD, chronic obstructive pulmonary disease.